Keywords: Eli Lilly, Boehringer Ingelheim, Diabetes research

Boehringer Ingelheim and Eli Lilly join forces to develop new diabetes treatments

Article | 12 January 2011

Print This

Germany’s largest independent pharmaceutical firm Boehringer Ingelheim and US drug major Eli Lilly (NYSE: LLY) yesterday announced a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in